AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) 35.4% LOWER; announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Company’s new drug application (NDA) for Zalviso (sufentanil sublingual tablet system). The Company is currently reviewing the FDA’s comments and requests contained in the CRL and plans to discuss these requests with the FDA.
Horizon Pharma (NASDAQ: HZNP) 26.7% LOWER; said it was verbally notified that in August 2014, two pharmacy benefit managers (PBMs), CVS Caremark (Caremark) and Express Scripts, Inc. (ESI), expect to announce DUEXIS® and VIMOVO® will no longer be on their